Safely treat high-risk lung tumors, delivering ablative doses with less toxicity
With more than 2 million cases diagnosed yearly, lung cancer is the most common type of cancer.1 And, with more than 1.7 million lung-cancer related deaths annually, also the deadliest.1 The high rate of mortality is attributed to two key factors: it is difficult to diagnose in early stages and is difficult to treat.2 Significant challenges include the location of the tumor, motion, and pulmonary comorbidity.3But today, MRIdian is changing the paradigm for high-risk lung cancer.
- MRIdian’s real-time tumor tracking and automatic beam gating make it possible for clinicians to treat lung tumors – even central and ultra-central lung tumors – with ablative doses of radiation while reducing toxicity to surrounding healthy tissue and sparing organs at risk.3-8
- Ablative doses have been shown to drive favorable treatment outcomes.3-5
- MRIdian may allow clinicians to treat patients with fewer doses – in some cases, a single radiation treatment.3,4,9
Learn how MRIdian works for lung
MRIdian for Lung Cancer
"One and Done Single Fraction"
Safely treating lung tumors with ablative doses can be challenging, from central and ultra central to single fraction requires a new level of precision and accuracy. See how Amsterdam University Medical Center is using MRIdian to treat smarter with ablative doses that work harder to destroy tumors and spare healthy tissues. Join this webinar where they will share their experience treating lung cancer with single fraction SABR. With the potential to improve outcomes, reduce side effects and deliver better patient quality of life, is this the future of cancer care? Come see what you may be missing.
Suresh Senan, MD, PhD, Professor of Clinical Experimental Radiotherapy
Miguel Palacios, PhD, Medical Physicist
1Ferlay, J., et al. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today
2Ciupki, B., 2020. Why Is Lung Cancer So Deadly? – National Foundation for Cancer Research. [online] NFCR. Available at: https://www.nfcr.org/blog/why-is-lung-cancer-so-deadly/ [Accessed 10 November 2020].
3Finazzi T, Haasbeek CJA, Spoelstra FOB, Palacios MA, Admiraal MA, Bruynzeel AME, Slotman BJ, Lagerwaard FJ, Senan S. (2020) Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. International Journal of Radiation Oncology • Biology • Physics (2020); 107(2),270-278.
4Finazzi, T., Palacios, M. A., Haasbeek, C. J. A., Admiraal, M. A., Spoelstra, F. O. B., Bruynzeel, A. M. E., et al. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. Radiotherapy and Oncology. 144 (2020) 46-52.
5Schneider BJ, Daly ME, Kennedy EB, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018;36(7):710–719.
6Henke, L. E., Olsen, J. R., Contreras, J. A., Curcuru, A., DeWees, T. A., Green, O. L., et al. (2018). Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial. Advances in Radiation Oncology. 4(1), 201–209.
7Song, S. Y., Choi, W., Shin, S. S., Lee, S. W., Ahn, S. D., Kim, J. H., et al. (2009). Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 66(1), 89–93.
8Finazzi, T., Palacios, M. A., Spoelstra, F. O. B., Haasbeek, C. J. A., Bruynzeel, A. M. E., Slotman, B. J., et al. (2019). Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors. International Journal of Radiation Oncology • Biology • Physics, 104(4), 933–941.
9Finazzi T, van Soerensen de Koste J, Palacios M, Spoelstra F, Slotman BJ, Haasbeek C, et al. (2020) Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. Phys Imag Radiat Oncol;14:17–23. https://doi.org/10.1016/j.
Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.